TRML Tourmaline Bio, Inc. Insider Trading

CEO Sandeep Chidambar buys 1,779 shares at $14.85 on 2024-08-21; prior 3 same-ticker buys all showed positive 90-day returns (+131.9% to +223.7%).

CEO Sandeep Chidambar purchased 1,779 shares for $26,418.15 on 2024-08-21, bringing his holdings to 7,000 shares and representing a 34.1% increase in his position. This buy follows a strong pattern in his same-ticker history: his 3 prior measurable buys at TRML (2023-10-24, 2023-10-26, and 2023-11-17) each delivered positive 90-day returns of +223.7%, +194.0%, and +131.9% respectively, with all 3 proving well-timed at the 90-day mark. The current stock price of $14.24 is 68.8% below the 52-week high of $45.64, creating a stark contrast with the timing pattern of his prior purchases. The company remains unprofitable with net income of -$17.5M, and the stock is down 7.9% over the past 30 days, yet the CEO's track record at this ticker—particularly the consistent 90-day outperformance and the pattern of well-timed entries—provides concrete evidence of his historical judgment on this specific security.

CEO Kulkarni buys 5,221 shares of TRML at $13.79 (Aug 2024); stock now $14.34, -68.6% from 52-week high despite insider's 100% 90-day win rate across prior trades.

Sandeep Chidambar Kulkarni, CEO of Tourmaline Bio, purchased 5,221 shares at $13.79 on 2024-08-16, establishing his first stake in the company while it trades -68.6% from its 52-week high of $45.64. His three prior purchases at TRML were all well-timed at the 90-day mark, with returns of +17.7%, +59.2%, and +67.5% respectively, and his cross-ticker track record shows a 100.00% 90-day win rate across 3 prior buys with an average 90d return of +183.2%. However, the company remains unprofitable with net income of $-17,487,000.00 over its most recent full fiscal year, and the stock has declined 2.5% in the 30 days since this purchase. The timing pattern of his prior accumulation suggests a historical ability to identify inflection points, yet the current negative fundamentals and recent price weakness present a tension worth monitoring.